Globe Newswire » Trang Công Nghệ

NOTICE TO DISREGARD -- ICARO Media Group

Globenewswire -

Digital Realty Announces Access to Oracle Cloud Infrastructure in Singapore via FastConnect

Globenewswire -

$Miltenyi Biomedicine presents primary analysis of the pivotal DALY 2-EU trial for second-line relapsed/refractory large B-cell lymphoma at the 67th American Society of Hematology (ASH) Annual Meeting$

Miltenyi Biomedicine presents primary analysis of the pivotal DALY 2-EU trial for second-line relapsed/refractory large B-cell lymphoma at the 67th American Society of Hematology (ASH) Annual Meeting

Globenewswire -

CAPHRA Raises Alarm over Legitimacy of WHO Tobacco Treaty.

Globenewswire -

Io Therapeutics presents today at the American Society for Hematology Annual Meeting, preclinical studies demonstrating combination treatment with BCMA CAR-T cells plus the company's RXR agonist compound IRX4204 has synergistic efficacy against human mul

Globenewswire -

Toripalimab Presents Long-Term Survival Benefits as 1st-line Treatment for Advanced Nasopharyngeal Carcinoma and Esophageal Squamous Cell Carcinoma Patients

Globenewswire -

Junshi Biosciences Announces Acceptance of the NDA for Roconkibart (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis

Globenewswire -

XEM THÊM TIN MỚI

Nổi bật :

NOTICE TO DISREGARD -- ICARO Media Group

Digital Realty Announces Access to Oracle Cloud Infrastructure in Singapore via FastConnect

Miltenyi Biomedicine presents primary analysis of the pivotal DALY 2-EU trial for second-line relapsed/refractory large B-cell lymphoma at the 67th American Society of Hematology (ASH) Annual Meeting

CAPHRA Raises Alarm over Legitimacy of WHO Tobacco Treaty.

Io Therapeutics presents today at the American Society for Hematology Annual Meeting, preclinical studies demonstrating combination treatment with BCMA CAR-T cells plus the company's RXR agonist compound IRX4204 has synergistic efficacy against human mul

Toripalimab Presents Long-Term Survival Benefits as 1st-line Treatment for Advanced Nasopharyngeal Carcinoma and Esophageal Squamous Cell Carcinoma Patients

Junshi Biosciences Announces Acceptance of the NDA for Roconkibart (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis

So sánh màn hình LG với Samsung và ViewSonic: Đâu là lựa chọn tối ưu?

Mua Đồ Công Nghệ Trả Góp: Hướng Dẫn So Sánh và Chọn Lựa Thông Minh

Lưu ngay cách gỡ bỏ phương thức thanh toán trên iPhone cực hiệu quả

Giải mã thần số học nghề nghiệp 2025 chi tiết, chuẩn xác

Bảng Quy đổi chữ cái thần số học là gì và cách chuyển đổi

CGTN: Những điều tạo nên thành công hai chiều trong hợp tác giữa Trung Quốc và Pháp

Bitget Releases Major Upgrades to GetAgent With Smarter Responses and Free Access for All Users

BÁO CÁO THỐNG KÊ CỦA WFDSA CHO THẤY HOẠT ĐỘNG BÁN HÀNG TRỰC TIẾP VẪN ỔN ĐỊNH TRONG NĂM 2024 TRONG BỐI CẢNH KINH TẾ TOÀN CẦU THAY ĐỔI

Yachting: Monaco, 7th 'Superyacht Chef Competition' opens for entries

Junshi Biosciences Announces Acceptance of the NDA for Roconkibart (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis